Vineeta Agarwala

Vineeta Agarwala, a general partner at Andreessen Horowitz, unveils how AI agents are set to revolutionize healthcare, improving drug development and patient care. Micky Malka, founder of Ribbit Capital, shares insights on enhancing financial accessibility and trust. Casey Neistat discusses engaging retro technology through ModRetro's M64. Zak Kukoff dives into the backlash against Trevor Milton's controversial interview. Meanwhile, Chris Samra introduces Waves camera glasses, merging AI with consumer tech, and Alex Hawkinson reveals how BrightAI is transforming infrastructure management with real-time solutions.

This is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Vineeta Agarwala, MD, PhD, discusses AI for drug discovery and her work as a physician. Topics include AI in drug discovery, biotech acquisitions in Seattle, tech-driven innovation in biotech investments, compassionate care in biotech, impact of AI in healthcare, and future of drug discovery in a high-tech world.

Scott Gottlieb, former head of the FDA and author of 'Uncontrolled Spread,' dives into the lessons learned from the COVID-19 pandemic. He discusses the critical role technology, particularly mRNA vaccine development, played in pandemic response and highlights failures in regulatory translation of science to policy. Joining him are Marc Andreessen, a prominent venture capitalist, and Vineeta Agarwala, a bio expert. They explore the need for improved genomic surveillance, private sector involvement in health infrastructure, and the ethical dilemmas of challenge trials for future preparedness.

Vineeta Agarwala, a physician-scientist and general partner at a16z who previously worked at GV, Flatiron Health, and the Broad Institute. She recounts her path from biophysics and MD-PhD training to building clinical-genomic data products. Conversations cover a16z’s founder-first investing approach, platform vs product trade-offs, the Lilly partnership, and how biotech and AI-driven consumer health are converging.